Clinical Trial Detail

NCT ID NCT01734512
Title PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of California, San Francisco, Novartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Indications

pilocytic astrocytoma

fibrillary astrocytoma

astrocytoma

Therapies

Everolimus

Age Groups: child adult

No variant requirements are available.